MXCT Form 4: CFO Purchases 50,000 Shares, Direct Holdings Rise to 161,811

Rhea-AI Filing Summary

MaxCyte CFO Douglas J. Swirsky reported a non-derivative insider purchase on Form 4: he acquired 50,000 shares of MaxCyte common stock at $1.29 per share on 08/13/2025, increasing his direct beneficial ownership to 161,811 shares. The filing lists the transaction in Table I as a purchase and indicates no derivative securities were reported.

Positive

• Insider purchase disclosed: CFO Douglas J. Swirsky acquired 50,000 shares at $1.29, increasing direct holdings to 161,811 shares.
• Clear Form 4 reporting: Transaction recorded in Table I as a non-derivative acquisition and Table II shows no derivatives.

Negative

• None.

Insights

Securities Analyst

TL;DR: CFO purchased 50,000 shares, recorded as a non-derivative acquisition; the report is a routine insider disclosure.

The Form 4 shows a direct acquisition of 50,000 common shares at $1.29, raising direct holdings to 161,811 shares. The transaction is recorded under Table I as a purchase and Table II contains no derivative entries. Based solely on the filing, this is a disclosed insider buy with limited contextual detail about broader ownership percentages or intent.

Corporate Governance Expert

TL;DR: Timely Form 4 reporting of an insider purchase by the CFO; no governance red flags are evident in the document.

The report names Douglas J. Swirsky as the reporting person and identifies his role as Chief Financial Officer. It documents a direct purchase of 50,000 shares at $1.29 and shows the updated direct beneficial ownership total of 161,811 shares. The filing format and disclosures are consistent with required Section 16 reporting based on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swirsky Douglas J

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		P		50,000	A	$1.29	161,811	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David Sandoval, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MaxCyte (MXCT) CFO Douglas J. Swirsky report on the Form 4?

The Form 4 reports a purchase of 50,000 shares of MaxCyte common stock at $1.29 per share on 08/13/2025, raising direct holdings to 161,811 shares.

How was the transaction classified on the Form 4 for MXCT?

The transaction is listed in Table I as a non-derivative purchase (reported with transaction code P) and no derivative securities are shown in Table II.

Does the Form 4 show any derivative transactions for MaxCyte insiders?

No. Table II of the filing contains no derivative securities reported for this transaction.

How many shares does the CFO directly own after the reported MXCT transaction?

Following the reported purchase, the filing shows the CFO directly owns 161,811 shares.

On what date was the insider purchase for MXCT executed?

The Form 4 records the transaction date as 08/13/2025.